摘要
目的观察环氧合酶-2抑制剂塞来昔布联合表皮生长因子受体单克隆抗体西妥昔单抗对人肠癌HCT-116细胞株生物学行为的影响。方法 Sanger测序法检测肠癌HCT-116细胞株的K-ras基因有无突变;塞来昔布、西妥昔单抗单独或联合作用于HCT-116细胞株,四甲基偶氮唑盐(MTT)法检测细胞增值抑制率,细胞划痕实验检测细胞的迁移能力,流式细胞术检测各组细胞的周期分布。结果 HCT-116细胞株K-ras基因12位点为野生型、13位点发生突变;塞来昔布及西妥昔单抗对HCT-116细胞的增殖抑制作用均呈剂量依赖性,两药联用可明显抑制HCT-116细胞的增殖;塞来昔布组和联合用药组均能明显抑制HCT-116细胞的迁移能力,而西妥昔单抗对细胞的迁移能力无明显抑制作用;塞来昔布组及联合用药组使细胞发生明显的G0/G1期阻滞(P<0.05)。结论塞来昔布与西妥昔单抗单药可抑制肠癌HCT-116细胞的生长,两者联用具有协同作用。
Objective To study the synergistic effect of cyclooxygenase-2 inhibitor Celecoxib and Epidermal growth factor receptor （EGFR） monoclonal antibody Cetuximab on human colorectal cancer cell line HCT-116. Methods K-ras gene of HCT-116 cell line was detected by Sanger sequencing. Cells were divided into control group, Celecoxib group, Cetuximab group and combined group. MTT assay was applied to determine the viability of colorectal cancer cell HCT-116, the cell cycle changes were ana- lyzed by flow cytometry,and wound healing assay was performed to assess the effects of drugs on cell mi- gration. Results K-ras gene was wild type at 12 codon and mutation at 13 codon in HCT-116 cell line. The celecoxib and cetuximab only inhibited proliferation of HCT-116 in a dose-dependent manner, The combination of celecoxib and cetuximab can decrease the proliferation of HCT-116 with a synergistic ac- tion;celecoxib and the combination significantly inhibited the ability of cell migration and induced G0/G1 phase arrested（P〈0.05）. Conclusion The proliferation of HCT-116 cell could be inhibited by celecoxib and cetuximab only, both drugs have synergistic effects.
出处
《福建医科大学学报》
2012年第6期385-391,共7页
Journal of Fujian Medical University
基金
福建省自然科学基金(2009J01119)
